Covance Doubles Service Capacity and Expertise for Metabolite Identification
To conduct metabolite identification supporting preclinical development and early human studies, Covance Inc. has announced a substantial increase in global capacity and expertise. The expansion increases Covance’s global scientific staff and equipment supporting metabolite identification to enable clients to start studies sooner and obtain results faster.
Covance’s global scientific staff dedicated to metabolite identification studies now includes 14 senior scientists located in Madison, Wisconsin and Harrogate, United Kingdom. New equipment brings the total instrumentation to five accurate mass Spectrometers, six QTrap mass spectrometers and access to nuclear magnetic resonance (NMR) analysis for unequivocal structural identification.
The additions at the Madison facility will better accommodate increased client demand resulting from the Food and Drug Administration’s (FDA) recent Guidance for Industry on Safety Testing of Drug Metabolites. The Guidance recommends when and how to identify and characterize drug metabolites whose nonclinical toxicity needs evaluation.
Covance has conducted hundreds of metabolite identification studies to date in Madison, Wisconsin and Harrogate, UK. Globally, Covance provides comprehensive drug metabolism services to pharmaceutical companies and hundreds of smaller pharmaceutical and biotech companies.
About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
